Physician profile
Alejandro C Alvarez
NPI 1508846304
$175,620.88
in general payments reported to CMS, 2019-2025
29 companies · $7,359 in 2025
The $7,359 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $31K · 2021: $40K · 2022: $29K · 2023: $13K · 2024: $5,911 · 2025: $7,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $5,167 · Travel and Lodging: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,960.00 |
| Food and Beverage | $5,166.52 |
| Travel and Lodging | $1,139.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $154,192.47 | 2019-2025 | Covera, Pristine, Fluency Endovascular Stent Graft |
| Medtronic, INC. | $10,618.61 | 2021-2025 | Ellipsys Vascular Access System, In.Pact Admiral, Chameleon |
| C. R. Bard, INC. & Subsidiaries | $2,300.00 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $2,198.94 | 2020-2024 | Viabahn Endoprosthesis With Propaten Bioactive Surface, Gore Viabahn Endoprosthesis, Gore Viabahn Endoprosthesis With Heparin |
| Inari Medical, INC. | $1,859.00 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Covidien LP | $1,163.06 | 2019-2020 | |
| Venturemed Group, INC. | $1,159.86 | 2020-2025 | Flex Vessel Prep System |
| Mozarc Medical US LLC | $630.02 | 2023-2025 | Chameleon, Argyle, Palindrome |
| Becton, Dickinson and Company | $213.87 | 2025 | Covera |
| Bard Access Systems, INC. | $166.26 | 2019 | |
| Vifor Pharma, INC. | $153.64 | 2019-2025 | Veltassa, Korsuva |
| C. R. Bard Foundation, INC. | $139.86 | 2019 | |
| Argon Medical Devices, INC. | $136.16 | 2025 | Clot Management |
| Glaxosmithkline, LLC. | $112.84 | 2023 | |
| Calliditas Therapeutics US INC. | $100.64 | 2023 | Tarpeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $93.16 | 2019-2021 | |
| Outset Medical INC | $75.00 | 2021 | |
| Cardiovascular Systems INC. | $51.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.13 | 2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $40.28 | 2024 | Xarelto |
| Mindray Ds USA, INC. | $30.02 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.80 | 2025 | Jardiance |
| Amgen INC. | $18.54 | 2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $17.60 | 2024 | Verquvo |
| Davol INC. | $17.18 | 2024 | Covera |
| Otsuka America Pharmaceutical, INC. | $16.86 | 2023 | Jynarque |
| Arjo INC. | $16.78 | 2025 | |
| Novo Nordisk INC | $15.19 | 2024 | Ozempic |
| Abbvie INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.